IN THE CLAIMS

Claims 1-71 (Canceled).

72. (Original) A method for treating cancer of the bladder comprising:

contacting the luminal surface of the bladder with a pretreatment composition comprising a transduction enhancing agent; and

subsequently contacting the luminal surface of the bladder with a composition comprising an oncolytic virus;

wherein the transduction enhancing agent has the following general formula (I) or the following general formula (II):



(I)



(II)

wherein X is a sulfur or oxygen atom, each R^2 is independently hydrogen or a moiety represented by:



and R^1 represents an alkyl or alkenyl group; and

wherein the luminal surface of the bladder is contacted with the pretreatment composition for at least 10 minutes.

73. (Original) The method of Claim 72, wherein R^1 comprises at least 12 carbon atoms.

74. (Original) The method of Claim 72, wherein each R^2 is hydrogen.

75. (Original) The method of Claim 72, wherein the transduction enhancing agent has the chemical formula:



wherein n is a positive integer.

76. (Original) The method of Claim 75, wherein n is 11 or greater.

77. (Original) The method of Claim 75, wherein n is 11.

78. (Original) The method of Claim 77, wherein the pretreating composition comprises about 0.025 to about 0.4 % by weight of the transduction enhancing agent.

79. (Original) The method of Claim 72, wherein the luminal surface of the bladder is contacted with the pretreatment composition for at least 20 minutes.

80. (Original) The method of Claim 79, wherein the luminal surface of the bladder is contacted with the composition comprising the oncolytic virus for 15 minutes or less.

81. (Original) The method of Claim 79, wherein the luminal surface of the bladder is contacted with the composition comprising the oncolytic virus for 10 minutes or less.

82. (Original) The method of Claim 72, wherein the transduction enhancing agent has the chemical formula:



wherein n is a positive integer.

83. (Original) The method of Claim 72, wherein the oncolytic virus is an oncolytic adenovirus.

84. (Original) The method of Claim 83, wherein the oncolytic adenovirus is CG8840.

85. (Original) The method of Claim 72, wherein the oncolytic virus composition comprises at least 4 x 10^{10} viral particles.

86. (Original) The method of Claim 72, wherein the transduction enhancing agent has the chemical formula:



where R^1 represents an alkyl or alkenyl group.

87. (Original) The method of Claim 86, wherein R^1 is represented by:



88. (Original) A method of treating cancer of the bladder comprising:

contacting the luminal surface of the bladder with a pretreatment composition comprising a transduction enhancing agent having a structure represented by the following general formula (I) or the following general formula (II):



(I)



(II)

wherein x is a positive integer; and

subsequently contacting the luminal surface of the bladder with a composition comprising an oncolytic virus;

wherein x is at least 11; and

wherein the oncolytic virus composition comprises at least 4×10^{10} viral particles.

89. (Original) The method of Claim 88, wherein x is 11.

90. (Original) The method of Claim 89, wherein the transduction enhancing agent has a structure represented by the general formula (I).

91. (Original) The method of Claim 90, wherein the pretreatment composition comprises about 0.1 wt.% of the transduction enhancing agent.

92. (Original) The method of Claim 88, wherein the oncolytic virus is an oncolytic adenovirus.

93. (Original) The method of Claim 92, wherein the oncolytic adenovirus is CG8840.

94. (Original) A composition comprising:

a transduction enhancing agent; and

an oncolytic virus;

wherein the transduction enhancing agent has a structure represented by the following general formula (I) or the following general formula (II):



(I)



(II)

wherein x is a positive integer; and

wherein the concentration of the transduction enhancing agent is less than 0.025 wt/% of the composition.

95. (Original) A method for treating cancer of the bladder comprising contacting a luminal surface of the bladder with the composition of Claim 94.